Annual report pursuant to Section 13 and 15(d)

Financial Instruments - Additional Information (Details)

v3.24.4
Financial Instruments - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Jan. 17, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Investments in privately held entities   $ 11.8  
Impairment loss $ 11.8    
Company Y      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration (up to) $ 2.6   $ 2.6